ReviewNature reviews. Gastroenterology & hepatology2012
Agents that act luminally to treat diarrhoea and constipation.
Review in Nature reviews. Gastroenterology & hepatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- A meta-analysis of berberine combined with brain-gut axis-targeted agents for diarrhoea-predominant irritable bowel syndrome.Frontiers in pharmacology · 2026Pooled it
- Guideline
- Management of Neurogenic Bowel Dysfunction in Adults after Spinal Cord Injury: Clinical Practice Guideline for Health Care Providers.Topics in spinal cord injury rehabilitationGuideline
- Trial
- Berberine alters the gut microbiota metabolism and impairs spermatogenesis.Acta biochimica et biophysica Sinica · 2024Article
- Efficacy and Molecular Mechanism of Quercetin on Constipation Induced by Berberine via Regulating Gut Microbiota.International journal of molecular sciences · 2024Article
- NIR-II and visible fluorescence hybrid imaging-guided surgery via aggregation-induced emission fluorophores cocktails.Materials today. Bio · 2022Article
- Neurogenic Bowel and Management after Spinal Cord Injury: A Narrative Review.Journal of personalized medicine · 2022Article
- Berberine and Cisplatin Exhibit Synergistic Anticancer Effects on Osteosarcoma MG-63 Cells by Inhibiting the MAPK Pathway.Molecules (Basel, Switzerland) · 2021Article
- Diagnosing Constipation Spectrum Disorders in a Primary Care Setting.Journal of clinical medicine · 2021Review
- Berberine alters gut microbial function through modulation of bile acids.BMC microbiology · 2021Article
- Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells.Biological research · 2019Article
- Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation.Translational research : the journal of laboratory and clinical medicine · 2017Article
- Luminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents.Frontiers in pharmacology · 2017Review
- Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancer.Oncotarget · 2016Article
- Pathogen-induced secretory diarrhea and its prevention.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2016Review
- Antiproliferation of berberine is mediated by epigenetic modification of constitutive androstane receptor (CAR) metabolic pathway in hepatoma cells.Scientific reports · 2016Article
- Significant pharmacokinetic differences of berberine are attributable to variations in gut microbiota between Africans and Chinese.Scientific reports · 2016Article
- CFTR activator increases intestinal fluid secretion and normalizes stool output in a mouse model of constipation.Cellular and molecular gastroenterology and hepatology · 2016Article
- A gastrointestinal anti-infectious biotherapeutic agent: the heat-treated Lactobacillus LB.Therapeutic advances in gastroenterology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diarrhoea and constipation are common clinical complaints that negatively affect quality of life, reduce work productivity and lead to considerable health-care expenditure. A variety of therapies have been used to treat these conditions. Unlike drugs that require systemic absorption to exert their effects, luminally acting agents improve diarrhoea and constipation by altering intestinal and/or colonic motility, as well as mucosal absorption and secretion, through a variety of mechanisms. Examples of luminally acting agents for diarrhoea include peripherally acting opiate analogues, enkephalinase inhibitors, bile-acid binding agents, nonabsorbed antibiotics, probiotics, bismuth-containing compounds, berberine and agents with possible effects on intestinal secretion or permeability. Luminally acting drugs for constipation include bulking agents, surfactants, osmotics, stimulants, chloride-channel activators, probiotics, drugs that increase delivery of bile acids to the colon and natural therapies such as prunes and hemp seed extract. As the physiological effects of luminally acting drugs are largely confined to the gastrointestinal tract, these agents are unlikely to cause adverse effects outside of the gastrointestinal tract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.